Clinical Trials for Mesothelioma Patients—A Study of Safety and Tolerability of Intravenous CRS-207: Inclusion Criteria

Read about the inclusion criteria for a current clinical trial about the safety and tolerability of intravenous CRS-207 in patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Inclusion Criteria:
1. Documented malignant epithelial mesothelioma, cancer of the pancreas or ovaries or non-small-cell lung cancer (NSCLC) and who have failed (or are not candidates for) standard therapy
2. ECOG Performance Status of 0 to 1, or Karnofsky Performance Status (KPS) of 80-100%
3. Adequate organ function as defined by study-specified laboratory tests
4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
5. Signed informed consent form
6. Willing and able to comply with study procedures

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.